Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB6GK4
|
|||
| Drug Name |
DS-1055
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Daiichi Sankyo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transforming growth factor beta activator LRRC32 (LRRC32) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04419532) A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Daiichi Sankyo. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.